Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
For many adolescents who may be squeamish about needles, anxious in clinical settings, or simply struggling with treatment adherence a once-daily pill could be transformative
Pettus J, Boeder SC, Christiansen MP et al (2022) Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
Assuming a 10% GLP-1 usage rate among overweight adults and a 20% usage rate among obese adults in the U.S., Roe (2025) estimates this could lead to a 3% reduction in total caloric demand, which amounts to 20 billion fewer calories of food consumed per day and about $1.2 billion less spent per week
launched Sitagliptin and its Fixed Dose Combinations (FDCs) for adults with Type 2 diabetes in India
US$ 22.97
US$ 21.58
US$ 27.67
US$ 27.84
